Abstract
CD40L, a member of the tumor necrosis factor family of ligands, plays a major role in immune responses via its receptor, CD40. Recently, CD40L has been detected on the surfaces of activated platelets and shown to activate endothelium. Here we further addressed the function of platelet CD40L. We show that absence of CD40L affects the stability of arterial thrombi and delays arterial occlusion in vivo. Infusion of recombinant soluble (rs)CD40L restored normal thrombosis, whereas rsCD40L lacking the KGD integrin-recognition sequence did not. CD40-deficient mice exhibited normal thrombogenesis. rsCD40L specifically bound to purified integrin αIIbβ3 and to activated platelets in a β3-dependent manner and induced platelet spreading. In addition, rsCD40L promoted the aggregation of either human or mouse platelets under high shear rates. Thus, CD40L appears to be an αIIbβ3 ligand, a platelet agonist, and necessary for stability of arterial thrombi.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
van Kooten, C. & Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol. 67, 2–17 (2000).
Henn, V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591–594 (1998).
Ramesh, N., Geha, R.S. & Notarangelo, L.D. CD40 ligand and the hyper-IgM syndrome. in Primary Immunodeficiency Diseases A Molecular and Genetic Approach (eds. Ochs, H.D., Smith, C.I.E. & Puck, J.M.) 233–249 (Oxford University Press, New York, 1999).
Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nature Med. 5, 1313–1316 (1999).
Schonbeck, U. & Libby, P. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58, 4–43 (2001).
Kotowicz, K., Dixon, G.L., Klein, N.J., Peters, M.J. & Callard, R.E. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 100, 441–448 (2000).
Miller, D.L., Yaron, R. & Yellin, M.J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc. Biol. 63, 373–379 (1998).
Henn, V., Steinbach, S., Buchner, K., Presek, P. & Kroczek, R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98, 1047–1054 (2001).
Aukrust, P. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100, 614–620 (1999).
Mach, F., Schonbeck, U., Bonnefoy, J.Y., Pober, J.S. & Libby, P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96, 396–399 (1997).
Lindmark, E., Tenno, T. & Siegbahn, A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler. Thromb. Vasc. Biol. 20, 2322–2328 (2000).
Celi, A. et al. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. USA 91, 8767–8771 (1994).
Andre, P., Hartwell, D., Hrachovinova, I., Saffaripour, S. & Wagner, D.D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci. USA 97, 13835–13840 (2000).
Graf, D. et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25, 1749–1754 (1995).
Scarborough, R.M. et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 268, 1066–1073 (1993).
Kawai, T., Andrews, D., Colvin, R.B., Sachs, D.H. & Cosimi, A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Med. 6, 114 (2000).
Denis, C. et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA 95, 9524–9529 (1998).
Ni, H. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Invest. 106, 385–392 (2000).
Lawler, J. & Hynes, R.O. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood 74, 2022–2027 (1989).
Larsen, C.P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438 (1996).
Kirk, A.D. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Med. 5, 686–693 (1999).
Schonbeck, U., Sukhova, G.K., Shimizu, K., Mach, F. & Libby, P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 97, 7458–7463 (2000).
Lutgens, E. et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc. Natl. Acad. Sci. USA 97, 7464–7469 (2000).
Melter, M. et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96, 3801–3808 (2000).
Giesen, P.L. et al. Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. USA 96, 2311–2315 (1999).
Ruoslahti, E. & Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. Science 238, 491–497 (1987).
Scarborough, R.M. et al. Barbourin. A GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 266, 9359–9362 (1991).
Charo, I.F., Nannizzi, L., Phillips, D.R., Hsu, M.A. & Scarborough, R.M. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. J. Biol. Chem. 266, 1415–1421 (1991).
Du, X.P. et al. Ligands “activate” integrin α IIb β 3 (platelet GPIIb-IIIa). Cell 65, 409–416 (1991).
Kawabe, T. et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1, 167–178 (1994).
Hodivala-Dilke, K.M. et al. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229–238 (1999).
Pullen, S.S. et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 38, 10168–10177 (1999).
Andre, P. et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 96, 3322–3328 (2000).
Andre, P. et al. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. Arterioscler. Thromb. Vasc. Biol. 16, 56–63 (1996).
Sakariassen, K.S., Kuhn, H., Muggli, R. & Baumgartner, H.R. Growth and stability of thrombi in flowing citrated blood: assessment of platelet-surface interactions with computer-assisted morphometry. Thromb. Haemost. 60, 392–398 (1988).
Phillips, D.R. & Agin, P.P. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J. Clin. Invest. 60, 535–545 (1977).
Acknowledgements
We thank L. Cowan for help with the preparation of the manuscript. Supported in part by National Heart, Lung and Blood Institute of the National Institutes of Health grants P01 HL56949 and R37 HL41002 (to D.D.W.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.P., K.S.S.P. and M.H. are employees of COR Therapeutics. P.A. became an employee of COR Therapeutics after completion of study.
Rights and permissions
About this article
Cite this article
André, P., Prasad, K., Denis, C. et al. CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism. Nat Med 8, 247–252 (2002). https://doi.org/10.1038/nm0302-247
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0302-247
This article is cited by
-
Predictive value of soluble CD40L combined with APACHE II score in elderly patients with sepsis in the emergency department
BMC Anesthesiology (2024)
-
Stable CAD patients show higher levels of platelet-borne TGF-β1 associated with a superior pro-inflammatory state than the pro-aggregatory status; Evidence highlighting the importance of platelet-derived TGF-β1 in atherosclerosis
Journal of Thrombosis and Thrombolysis (2022)
-
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy
Journal of Thrombosis and Thrombolysis (2022)
-
The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
Journal of Cardiovascular Translational Research (2021)
-
IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn’s disease and new therapeutic targets
Archives of Pharmacal Research (2021)